Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLEA: Immunotherapy for Olea Pollen Allergy
NCT00831025Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Jan 2008
- Primary completion
- Jan 2013
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olea europaea pollen extract in allergic rhinitis (AR) and Rhinoconjunctivitis (RC) (2 arms), sponsored by LETI Pharma. Primary endpoint: Symptoms and medication score at 2 years. Started Jan 2008; status: completed.
02
Drugs
olea europaea pollen extract
03
Conditions
allergic rhinitis (AR)Rhinoconjunctivitis (RC)
Beyond the preview
Go deeper on NCT00831025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831025.